Complete loss of<i>SLC30A8</i>in humans improves glucose metabolism and beta cell function
ABSTRACT Genetic association studies have demonstrated that partial loss ofSLC30A8function protects against type 2 diabetes (T2D) in humans, but the impact of complete loss ofSLC30A8function remains unknown. From whole-exome and genome sequencing of 100,814 participants in the Pakistan Genome Resource, we identified fifteenSLC30A8knockouts, including homozygotes for a variant enriched in South Asians (Gln174Ter) and 615 heterozygotes for loss-of-function (LoF) variants. T2D risk was lower inSLC30A8LoF hetero- and homozygotes, and the protective effect strengthens in a gene dose-dependent manner (ORadditive=0.63 [0.53-0.78, p=7.5E-07], ORrecessive=0.27 [0.09-0.80, p=0.018]). Recall-by-genotype ofSLC30A8LoF hetero- and homozygotes and their family members with oral glucose tolerance tests showed a gene dose-dependent reduction in glucose levels coupled with elevated insulin. Corrected Insulin Response, Disposition Index, and Insulin Sensitivity Index in LoF hetero- and homozygotes indicated higher glucose-stimulated insulin secretion with preserved beta cell function. These data suggest that therapeutic knockdown ofSLC30A8, up to and including complete knockout, may treat T2D safely and effectively..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 10. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lamarche, Lindsey B. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2024.04.05.24305397 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI043188001 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI043188001 | ||
| 003 | DE-627 | ||
| 005 | 20240411090554.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240408s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.04.05.24305397 |2 doi | |
| 035 | |a (DE-627)XBI043188001 | ||
| 035 | |a (biorXiv)10.1101/2024.04.05.24305397 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lamarche, Lindsey B. |e verfasserin |0 (orcid)0000-0002-7200-3150 |4 aut | |
| 245 | 1 | 0 | |a Complete loss of<i>SLC30A8</i>in humans improves glucose metabolism and beta cell function |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Genetic association studies have demonstrated that partial loss ofSLC30A8function protects against type 2 diabetes (T2D) in humans, but the impact of complete loss ofSLC30A8function remains unknown. From whole-exome and genome sequencing of 100,814 participants in the Pakistan Genome Resource, we identified fifteenSLC30A8knockouts, including homozygotes for a variant enriched in South Asians (Gln174Ter) and 615 heterozygotes for loss-of-function (LoF) variants. T2D risk was lower inSLC30A8LoF hetero- and homozygotes, and the protective effect strengthens in a gene dose-dependent manner (ORadditive=0.63 [0.53-0.78, p=7.5E-07], ORrecessive=0.27 [0.09-0.80, p=0.018]). Recall-by-genotype ofSLC30A8LoF hetero- and homozygotes and their family members with oral glucose tolerance tests showed a gene dose-dependent reduction in glucose levels coupled with elevated insulin. Corrected Insulin Response, Disposition Index, and Insulin Sensitivity Index in LoF hetero- and homozygotes indicated higher glucose-stimulated insulin secretion with preserved beta cell function. These data suggest that therapeutic knockdown ofSLC30A8, up to and including complete knockout, may treat T2D safely and effectively. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Koch, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Khalid, Shareef |e verfasserin |4 aut | |
| 700 | 1 | |a Zaman, Maleeha |e verfasserin |4 aut | |
| 700 | 1 | |a Zessis, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Clement, Matthew E. |e verfasserin |4 aut | |
| 700 | 1 | |a Denning, Daniel P. |e verfasserin |4 aut | |
| 700 | 1 | |a Goldfine, Allison B. |e verfasserin |4 aut | |
| 700 | 1 | |a Abbasi, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Harrow, Jennifer L |e verfasserin |4 aut | |
| 700 | 1 | |a Underwood, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Tsunoyama, Kazuhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Asaumi, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Kou, Ikuyo |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Flores, Juan L |e verfasserin |4 aut | |
| 700 | 1 | |a Shuldiner, Alan R. |e verfasserin |4 aut | |
| 700 | 1 | |a Rasheed, Asif |e verfasserin |4 aut | |
| 700 | 1 | |a Jahanzaib, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Mian, Muhammad Rehan |e verfasserin |4 aut | |
| 700 | 1 | |a Liaqat, Muhammad Bilal |e verfasserin |4 aut | |
| 700 | 1 | |a Abdulsalam, Usman |e verfasserin |4 aut | |
| 700 | 1 | |a Sultana, Riffat |e verfasserin |4 aut | |
| 700 | 1 | |a Jalal, Anjum |e verfasserin |4 aut | |
| 700 | 1 | |a Saeed, Muhammad Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Abbas, Shahid |e verfasserin |4 aut | |
| 700 | 1 | |a Memon, Fazal Rehman |e verfasserin |4 aut | |
| 700 | 1 | |a Ishaq, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Gurtan, Allan M. |e verfasserin |4 aut | |
| 700 | 1 | |a Dominy, John E. |e verfasserin |4 aut | |
| 700 | 1 | |a Saleheen, Danish |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 10. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:10 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.04.05.24305397 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 10 |c 04 | ||